model_params = {'model': 'nex-agi/deepseek-v3.1-nex-n1:free', 'input': '20140416-latest-protein-protein-compounds.txt', 'reasoning': {'effort': 'high'}, 'text': {'verbosity': 'medium'}}

# 1. SUMMARY

This 2014 *In the Pipeline* blog post by Derek Lowe reviews an academic paper on protein–protein interaction (PPI) "hot spots" as targets for small-molecule drug discovery. The author frames the well-known challenge: while binding "hot spots" exist and would be desirable drug targets, finding small molecules that can productively occupy these sites and disrupt the PPI is notoriously difficult. A core tension is that true hot-spot binding sites must offer enough energetics for a drug to bind tightly, yet many interaction surfaces are too flat and featureless to concentrate binding energy onto a small molecule. Lowe also raises doubts about the claim that existing screening libraries are structurally "wrong" for PPI targets, noting that many libraries already contain large, flat ("lunker") compounds that might fit such sites; he suspects these molecules would still pose severe pharmacokinetic and formulation challenges even if they did show activity.

# 2. HISTORY

Between 2014 and the present, the PPI field moved from niche aspiration to a robust, clinically validated frontier in drug discovery, though progress was highly target-dependent. By the late 2010s, multiple PPI modulators achieved regulatory approval. Key examples include:
- **Venetoclax (ABT-199, approved 2016):** A landmark BCL-2 inhibitor that blocks the BCL-2/BAX PPI to induce apoptosis in certain leukemias. Its success demonstrated that high-affinity PPI disruption with oral bioavailability was achievable.
- **Selinexor (approved 2019):** Inhibits XPO1-mediated nuclear export by interfering with the XPO1-cargo protein interaction.
- **Several MCL-1 inhibitors:** Entered clinical trials after 2016, further validating the BCL-2 family PPI axis as druggable.
- **Bromodomain and Extra-Terminal (BET) inhibitors:** Though many stalled due to toxicity, they proved that PPIs involving transcriptional co-activators could be targeted.
- **PROTACs (PROteolysis-Targeting Chimeras) and molecular glues (e.g., lenalidomide analogues):** These approaches surged after 2014, redirecting PPIs to induce degradation of previously undruggable targets.

Methodologically, fragment-based drug discovery, DNA-encoded libraries (DEL), and structure-guided design became standard tools. The "hot spot" concept integrated with AlphaFold and molecular dynamics to enable *in silico* screening and rational design against PPI interfaces. Despite successes, challenges remain: many PPIs are still intractable, and achieving potency and oral bioavailability often requires larger, more lipophilic molecules than typical drugs.

# 3. PREDICTIONS

## Matched
- **Difficulty in drugging PPIs persisted:** Lowe’s skepticism was largely vindicated. Even with tools like DEL and fragment screening, hit rates for PPIs remained lower than for orthosteric enzyme inhibitors.
- **PK and formulation hurdles were real:** Many early, flat-and-large PPI inhibitors faced poor solubility, permeability, and metabolic stability, though medicinal chemists ultimately found ways to balance affinity, size, and lipophilicity.
- **Lowe’s doubt about "library bias" as the primary blocker was correct:** The problem was less about missing exotic ring systems and more about the physics of disrupting large, shallow interfaces. DEL and fragment libraries later proved valuable precisely because they explored simpler chemotypes that could be grown into drug-like molecules.

## Wrong, or eclipsed by events
- **The near-term validation of druggability:** Lowe’s tone was cautiously pessimistic, but within two years of the post, **venetoclax** was approved. Rapidly thereafter, multiple BCL-2/MCL-1/BET programs entered trials. This shift suggests the PPI field was closer to breakout success in 2014 than the article implied.
- **Underestimation of modalities beyond orthosteric small molecules:** The piece did not anticipate how profoundly **PROTACs** and **molecular glues** would reshape PPI targeting. These modalities exploit PPIs to trigger degradation or neomorphic interactions, effectively turning an undruggable surface into a tractable problem in a different way.

# 4. INTEREST

**8**

This article ranks in the 8th decile (top 20%, around the 80–89 percentile). Its long-term importance stems from capturing a turning point: while Lowe voiced widespread skepticism in 2014, the field was already on the cusp of breakthrough validations (notably BCL-2 inhibition). The post provides a valuable historical benchmark for how "difficult" targets were perceived against the backdrop of clinical progress that followed. The core challenge—balancing thermodynamic binding energy across shallow interfaces—remains central to structure-based drug design, and advances in computational modeling still aim to solve the problems Lowe articulated. It also reflects the persistent truth that early-stage optimism and later-stage delivery rarely align neatly in drug discovery.